NewsEvents

Your Yourlocation: Home > Comparison of salmeterol /fluticasone and tiotropium bromide(136310-93-5) in preventing acute exacerbation of COPD

Jarwiga A. published a randomized, double-blind, placebo-controlled, parallel-group study of 1323 patients in the 17th edition of American Journal of Respiratory and Critical Care Medicine, comparing salmeterol / fluticasone and tiotropium bromide(136310-93-5) to prevent acute exacerbation of COPD.

The primary end point of the study was acute exacerbation after health care intervention, and other end points included health status (SGRQ scale), mortality, adverse events and withdrawal studies. In the study of withdrawal rates, the tiotropium bromide(136310-93-5) group was higher than 29% (P = 0.005) in the salmeterol / fluticasone group. At the annual acute exacerbation rate, the salmeterol / fluticasone group was 1.28 and the tiotropium group was 1.32 (the ratio was 0.967, 95% confidence interval [CI] (0.836-1.119), P = 0.656). In the SGRQ total score (second year), salmeterol / fluticasone group was lower than tiotropium group and was statistically significant (2.1 points; 95% CI, 0.1-4.0; P = 0.038). The mortality rate of salmeterol / fluticasone was lower than that of tiotropium bromide, both of which were statistically significant, with 21 patients (3%) died and 38 patients (6%) died (P = 0.032 ).

The final conclusion is that the acute exacerbation rates of the two groups are not statistically different and that more patients in the tiotropium bromide(136310-93-5) treatment group have failed to complete the study. In terms of health status, there was a statistically significant difference between the two groups, and an unexpected finding was that the mortality rate was lower in the salmeterol / fluticasone-treated group.

Address:211#Zhengfeng Building,Huanbaokejiyuan, Gaoxinkaifaqu, Jinan,250100,China TEL:086-531-82375818 Tiotropium Bromide
© Copyright(C)2014 JINAN DEXINJIA BIO & TECH CO., LTD All Rights Reserved